Cyclosporine: Decreased therapeu-tic effect; increased risk of nephrotoxicity. Moni-tor patient and cyclosporine levels.
Methotrexate: Increases levels. Monitor methotrex-ate levels.
Oral anticoagulants: Inhibited hepatic metabo-lism of anticoagulants, enhancing anticoagulant effects. Monitor PT INR.
Oral sulfonylureas: Enhances their hypoglycemic effects; monitor serum glucose.
PABA: Antagonizes sulfonamide effects; monitor serum glucose.
Phenytoin: Hepatic clearance may be decreased and half-life prolonged. Monitor patient closely; monitor phenytoin level.
Zidovudine: Serum levels may be increased due to reduced renal clearance. Monitor serum zi-dovudine level.
Drug-lifestyle:Sun exposure: Photosensitivity reaction may occur. Advise parent to take pre-cautions with children being exposed to sunlight. |